Furthermore, this treatment induced a reduction of C16:0 ceramides plasma levels, resulting in improved glucose tolerance and insulin sensitivity, confirming the strict correlation between ceramide, obesity and insulin resistance again. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.